Clinical Trials - 57 patients have been dosed in the FIRCE-1 Phase 2 clinical study of firi-cel, with interim analysis expected in 1H25[1] - The Independent Data Monitoring Committee recommended the continuation of the FIRCE-1 study without modification[3] - CARGO anticipates submitting the IND application for CRG-023 in Q1 2025, with the first patient dosed planned for 2025[4] - CARGO will present pre-clinical data for CRG-023 at the ASH 2024 meeting, highlighting its durable anti-tumor activity[4] Financial Performance - Research and Development (R&D) expenses for Q3 2024 were $35.9 million, compared to $22.2 million in Q3 2023, representing a 61.6% increase[5] - General and Administrative (G&A) expenses for Q3 2024 were $11.2 million, up from $6.5 million in Q3 2023, a 72.5% increase[5] - Net loss for Q3 2024 was $41.9 million, or $0.88 per share, compared to a net loss of $35.5 million, or $0.47 per share in Q3 2023[5] - Total operating expenses for Q3 2024 were $47.1 million, compared to $28.7 million in Q3 2023, a 64% increase[8] Cash Position - Cash, cash equivalents, and marketable securities as of September 30, 2024, totaled $404.8 million, sufficient to fund operations through 2026[5] Leadership Changes - Anup Radhakrishnan has been appointed as COO in addition to his role as CFO, enhancing operational leadership[2]
Cargo Therapeutics(CRGX) - 2024 Q3 - Quarterly Results